drugset / Trial / NCT07074496

Efficacy, Safety, and Pharmacokinetics of ThisCART19A Combined With Olverembatinib in Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.

NCT07074496

NaSingle-groupOpen-labelTreatment

Summary

This is an Open, Prospective, Single-arm Study, which is designed to evaluate the efficacy, safety and pharmacokinetics of ThisCART19A Combined With Olverembatinib for the treatment of Newly Diagnosed Ph-positive lymphoblastic leukemia.

Timeline

Start
2024-01-01
Primary completion
2025-11-15
Completion
2028-07-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Olverembatinib Small molecule Oral
Subject ThisCART19A Cell therapy Intravenous
Background Cyclophosphamide Other / unclassified
Background Fludarabine Small molecule